Related Experiment Video
Updated: Jun 19, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Role of genetic testing in arrhythmogenic right ventricular cardiomyopathy/dysplasia
C Barahona-Dussault1, B Benito, O Campuzano
1Institut de Cardiologie de Montréal, Montréal, Québec, Canada.
Insights
Genetic testing aids arrhythmogenic right ventricular cardiomyopathy (ARVC/D) diagnosis, especially for uncertain cases. Novel mutations are common, limiting known mutation screening, but specific variants influence disease severity.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a heritable heart muscle disease.
- Diagnostic challenges exist, particularly in individuals not fully meeting established criteria.
- Genetic factors are implicated in ARVC/D pathogenesis.
Purpose of the Study:
- To evaluate the utility of genetic testing in diagnosing ARVC/D.
- To explore the role of genetic variations in ARVC/D phenotype.
- To assess the value of screening for known mutations versus broader genetic approaches.
Main Methods:
- Cohort study of patients with confirmed or suspected ARVC/D.
- Genetic testing including analysis of known and novel mutations.
- Correlation of genetic findings with clinical phenotype and disease severity.
Main Results:
- Genetic testing is valuable for confirming ARVC/D, especially in borderline cases.
- A high proportion of novel mutations are identified, suggesting limited utility of known mutation screening alone.
- Specific genetic variations, including compound mutations and the P366L polymorphism, are associated with disease phenotype and severity.
Conclusions:
- Genetic testing is a crucial tool for ARVC/D diagnosis and family screening.
- Focusing solely on known mutations is insufficient due to the prevalence of novel variants.
- Genetic variations significantly influence the clinical presentation and prognosis of ARVC/D patients.
Abstract:
In a cohort of patients with confirmed or suspected arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D), genetic testing is useful in confirming the diagnosis, particularly in individuals who do not completely fulfil Task Force criteria for the disease, thereby also enabling the adoption of preventive measures in family members. Due to the high percentage of novel mutations that are expected to be identified in ARVC/D, the use of genetic screening technology based on the identification of known mutations seems to have very restricted value. Our results support that the presence of certain genetic variations could play a role in the final phenotype of patients with ARVC/D, where single and compound mutation carriers would have more symptomatic forms of the disease and the polymorphism P366L could be associated to a more benign phenotype.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Dysrhythmias V: Evaluating Dysrhythmias
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Mechanism of Cardiac Arrhythmias

